ERBB2 and breast carcinoma: At doses of 25 and 50 μM, compound 6 inhibited the proliferation of BT474, MCF-7, and SkBr3 breast cancer cells, and the proteins Her2 and Akt were degraded by compound 6 in BT474 and MCF-7 breast cancer cells.